Altis Biosystems, Inc.
Altis Biosystems aims to transform preclinical therapeutic development with best-in-class human cell-based model systems, reducing reliance on animal models and accelerating drug discovery. They develop advanced in vitro platforms like RepliGut® Systems derived from human stem cells to provide physiologically relevant data for drug screening, disease modeling, and microbiome research, ultimately improving clinical trial outcomes and human health.
Industries
Nr. of Employees
small (1-50)
Altis Biosystems, Inc.
Durham, North Carolina, United States, North America
Products
Intestinal epithelial model kits (12- and 96-well transwell formats)
Complete kits containing precoated membrane-support multiwell plates, region-specific primary intestinal stem cells, and culture media to establish polarized human intestinal epithelial monolayers in-house.
Sterile human intestinal mucus samples
Harvested sterile mucus derived from primary intestinal epithelial cultures intended for microbiome interaction studies and drug delivery research.
Intestinal epithelial model kits (12- and 96-well transwell formats)
Complete kits containing precoated membrane-support multiwell plates, region-specific primary intestinal stem cells, and culture media to establish polarized human intestinal epithelial monolayers in-house.
Sterile human intestinal mucus samples
Harvested sterile mucus derived from primary intestinal epithelial cultures intended for microbiome interaction studies and drug delivery research.
Services
Custom assay and project services
Tailored experimental studies executed by company scientists using primary intestinal epithelial platforms; assays customizable to client specifications.
Rapid inflammation screening (InflammaScreen)
High-throughput screening service to assess compound effects on epithelial inflammatory responses using cytokine stimulation and secretion endpoints.
Stem-cell-based GI toxicity screening (StemTox)
Assay service using primary epithelial cultures to predict gastrointestinal toxicity and barrier disruption risk of therapeutic agents.
In vitro DMPK and permeability services
Permeability and absorption assays using primary intestinal epithelium to support DMPK evaluations and oral bioavailability prediction.
Turnkey project execution using planar and crypt model formats
End-to-end project execution using either planar membrane-supported monolayers or crypt-region models for studies ranging from toxicity to disease modeling.
Custom assay and project services
Tailored experimental studies executed by company scientists using primary intestinal epithelial platforms; assays customizable to client specifications.
Rapid inflammation screening (InflammaScreen)
High-throughput screening service to assess compound effects on epithelial inflammatory responses using cytokine stimulation and secretion endpoints.
Stem-cell-based GI toxicity screening (StemTox)
Assay service using primary epithelial cultures to predict gastrointestinal toxicity and barrier disruption risk of therapeutic agents.
In vitro DMPK and permeability services
Permeability and absorption assays using primary intestinal epithelium to support DMPK evaluations and oral bioavailability prediction.
Turnkey project execution using planar and crypt model formats
End-to-end project execution using either planar membrane-supported monolayers or crypt-region models for studies ranging from toxicity to disease modeling.
Expertise Areas
- Intestinal epithelial in vitro modeling
- Preclinical GI toxicity screening
- In vitro ADME and permeability testing
- Inflammation and immunology assays
Key Technologies
- Membrane-supported planar transwell culture (12- and 96-well)
- Primary human intestinal stem-cell-derived monolayers
- Transepithelial electrical resistance (TEER) measurement
- Cytokine stimulation assays (TNF-α, IFN-γ) and cytokine secretion readouts (e.g., IL-8)